Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical

Next Previous
X
Search
Drug Profile

Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; OP-01-Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical; Oral RARa agonist - Syros Pharmaceuticals; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; Gyre Therapeutics; Nagoya University; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia
  • Phase I/II Pancreatic cancer
  • No development reported Neutropenia; Solid tumours
  • Discontinued Crohn's disease; HER2 positive breast cancer; Liver cancer; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 12 Aug 2024 Adverse events and efficacy data from a phase II for Acute myeloid leukaemia released by Syros Pharmaceuticals
  • 12 Aug 2024 Syros Pharmaceuticals discontinues enrolment in its phase II SELECT-AML-1 trial in Acute myeloid leukaemia (Combination therapy, First-line therapy, Newly diagonsed) in USA and France (PO) (NCT04905407)
  • 10 Apr 2024 Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical receives Fast Track designation for Acute myeloid leukaemia [PO] (Combination therapy, First-line therapy) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top